These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3768243)

  • 21. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonlinear pharmacokinetics of unbound propranolol after oral administration.
    Straka RJ; Lalonde RL; Pieper JA; Bottorff MB; Mirvis DM
    J Pharm Sci; 1987 Jul; 76(7):521-4. PubMed ID: 3668812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
    Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin.
    Anthony L; Koshakji R; Wood AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):297-300. PubMed ID: 2776392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    Lankford SM; Maskasame C; Bai SA
    Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of aging on the oxidative and conjugative metabolism of propranolol.
    Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
    Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereoselective disposition and glucuronidation of propranolol in humans.
    Silber B; Holford NH; Riegelman S
    J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereoselective clearance and distribution of intravenous propranolol.
    Olanoff LS; Walle T; Walle UK; Cowart TD; Gaffney TE
    Clin Pharmacol Ther; 1984 Jun; 35(6):755-61. PubMed ID: 6734027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet.
    Fagan TC; Walle T; Oexmann MJ; Walle UK; Bai SA; Gaffney TE
    Clin Pharmacol Ther; 1987 Apr; 41(4):402-6. PubMed ID: 3829577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity.
    von Bahr C; Hermansson J; Lind M
    J Pharmacol Exp Ther; 1982 Aug; 222(2):458-62. PubMed ID: 7097564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propranolol absorption in untreated coeliac disease.
    Sandle GI; Ward A; Rawlins MD; Record CO
    Clin Sci (Lond); 1982 Jul; 63(1):81-5. PubMed ID: 7083769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates.
    Walle T
    Drug Metab Dispos; 1985; 13(3):279-82. PubMed ID: 2861983
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog.
    Bai SA; Easterling DE; Wilson MJ; Walle UK; Haney CA; Peet NP; Pruett JK; Walle T
    Drug Metab Dispos; 1989; 17(5):495-505. PubMed ID: 2573492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.